Phase 3 IsKia trial of Isatuximab+ KRd in Multiple Myeloma [ASH 2023] Multiple Myeloma 1 Min Read63 Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate…
